Manufacturer: ADL

AMGEN

BLINCYTO®
(blinatumomab)
for Injection

35 mcg/vial

35 mcg/vial

For Intravenous Infusion Only

Keep medicine out of reach of children.
Jauhi ubat daripada kanak-kanak.

Controlled Medicine/ Ubat Terkawal

Dosage – See Package Insert.

See Package Insert for complete instructions on preparation and administration.

1033822

Product Registration Holder:
Amgen Biopharmaceuticals Malaysia Sdn Bhd
Common Ground, 1 Powerhouse,
Horizon Penthouse, No. 1,
Persiaran Bandar Utama, Bandar Utama,
47800 Petaling Jaya, Selangor, Malaysia.

Manufactured by:
Amgen Technology (Ireland) Unlimited Company
Pottery Road, Dun Laoghaire,
Co. Dublin, Ireland.

Released by:
Amgen Manufacturing Limited LLC
State Road 31, Kilometer 24.6,
Juncos, Puerto Rico 00777, USA.

8 715131 015008

AMGEN

BLINCYTO®
(blinatumomab)
for Injection

35 mcg/vial

AMGEN

BLINCYTO®
(blinatumomab)
for Injection

35 mcg/vial

35 mcg/vial

Each vial of BLINCYTO® contains blinatumomab (35 mcg), citric acid monohydrate (3.35 mg), lysine hydrochloride (23.23 mg), polysorbate 80 (0.64 mg), and trehalose dehydrate (95.5 mg), sodium hydroxide as needed for adjustment to pH 7.0. After reconstitution with 3 mL preservative free Sterile Water for Injection, USP, the resulting concentration is 12.5 mcg/mL blinatumomab.

Each vial of Intravenous Solution Stabilizer for BLINCYTO® contains citric acid monohydrate (52.5 mg), lysine hydrochloride (2283.8 mg), polysorbate 80 (10 mg), sodium hydroxide as needed for adjustment to pH 7.0, and Sterile Water for Injection, USP.

1 x BLINCYTO® Single Use Vial
1 x IV Solution Stabilizer Vial

MAL16105053ACZ

LOT
MFG
EXP
1033822

AMGEN

BLINCYTO®
(blinatumomab)
for Injection

35 mcg/vial

35 mcg/vial

For Intravenous Infusion Only

Store at 2°C to 8°C.

Store in carton to protect from light.

DO NOT SHAKE reconstituted solution.

No Preservative

Single Use Vial –
Discard unused portion.

BLINCYTO® is a registered trademark owned or licensed by Amgen Inc., its subsidiaries, or affiliates.

Manufacturer: BIP